Clinical Guides
Disseminated Intravascular Coagulation
A clinically focused clinical guide to recognising, diagnosing, and stabilising disseminated intravascular coagulation while treating its cause in Indian emergency, obstetric, oncology, and critical-care settings.
MedNext Academy | 15 min read
Disseminated Intravascular Coagulation
A clinically focused clinical guide to recognising, diagnosing, and stabilising disseminated intravascular coagulation while treating its cause in Indian emergency, obstetric, oncology, and critical-care settings.
Summary
Disseminated intravascular coagulation (DIC) is an acquired, life-threatening syndrome in which systemic coagulation activation, endothelial injury and dysregulated fibrinolysis produce microvascular thrombosis, consumption of platelets and coagulation factors, bleeding, organ dysfunction or combinations of these. It is never a standalone aetiological diagnosis. Sepsis, major trauma, obstetric catastrophe, malignancy—especially acute promyelocytic leukaemia—severe tissue injury and selected vascular or immune disorders are recognised triggers. The phenotype varies with cause and phase: sepsis often has suppressed fibrinolysis and organ failure, whereas obstetric DIC or acute promyelocytic leukaemia can show intense fibrinolysis and catastrophic haemorrhage.
No single laboratory result proves or excludes DIC. Diagnosis integrates an appropriate underlying disorder, clinical change and serial platelet count, prothrombin time, fibrin-related markers and fibrinogen. The established ISTH overt-DIC score is widely used, but early disease can precede a positive overt score. The 2025 ISTH Scientific and Standardization Committee communication updates the conceptual definition and proposes phase- and cause-aware scoring; adoption and local validation are still evolving, so clinicians must identify which system their institution uses. A stable fibrinogen does not exclude DIC because it is an acute-phase reactant.
The cornerstone is rapid treatment of the precipitating condition alongside organ support and targeted haemostatic therapy. Blood components are used for clinically significant bleeding or a high-risk procedure, not merely to normalise numbers. Anticoagulant or antifibrinolytic treatment is context-dependent and can cause harm when copied across phenotypes. DIC is dynamic: repeat clinical and laboratory assessment is essential. This educational draft remains quarantined following MedNext Clinical Team review and cannot replace a critical-care, obstetric, oncology, trauma, transfusion or local massive-haemorrhage protocol.
How Common Is It?
The frequency of DIC cannot be expressed as one general-population prevalence because it is a complication of heterogeneous acute illnesses. Published estimates depend on the trigger population, diagnostic score, sampling time, laboratory availability and whether early or only overt disease is counted. Intensive-care studies enriched for septic shock will not represent obstetric units, trauma centres or oncology wards. Changes in scoring can alter apparent incidence without changing biology. The updated ISTH framework specifically recognises a progression from an early potentially asymptomatic phase to advanced haemorrhage or organ dysfunction, which further limits comparison with older overt-DIC studies.
Clinical burden is substantial because DIC identifies severe underlying disease and contributes to multiorgan injury, procedural bleeding, transfusion exposure and death. In sepsis, inflammation and coagulation interact; in acute promyelocytic leukaemia, haemorrhage can occur before definitive classification; in placental abruption or amniotic-fluid embolism, deterioration may be abrupt. Trauma-associated coagulopathy overlaps with but is not identical to DIC. A hospital should therefore measure trigger-specific cases rather than pool all abnormal coagulation tests under one label.
Indian incidence is not securely defined by a single contemporary national registry. Referral hospitals see a selected and often late-presenting population, while smaller centres may lack D-dimer, fibrinogen, specialist film review or round-the-clock blood components. Coding data can confuse DIC with liver disease, dilutional coagulopathy or massive haemorrhage. Actionable local measures include time from trigger recognition to antibiotics, delivery or definitive haemorrhage control; serial-score completion; component availability; inappropriate prophylactic transfusion; maternal or trauma transfer delay; and organ outcomes. International frequencies and treatment effects cannot be directly projected onto Indian case mix, antimicrobial resistance, blood supply or critical-care capacity.
Risk Factors
DIC requires a potent underlying stimulus. Bacterial sepsis and septic shock are major causes, but severe viral, fungal or parasitic infection may also activate systemic coagulation. Major trauma, burns, pancreatitis, heatstroke, shock and extensive tissue destruction provide tissue factor, inflammatory and endothelial triggers. Obstetric causes include placental abruption, amniotic-fluid embolism, retained dead fetus, severe postpartum haemorrhage, uterine rupture, acute fatty liver of pregnancy and severe hypertensive disease with HELLP-spectrum pathology. Prompt source, delivery or haemorrhage control matters more than debating the label while physiology worsens.
Malignancy-related DIC occurs particularly with acute promyelocytic leukaemia and can accompany mucin-producing adenocarcinoma or advanced cancer. APL is an emergency because hyperfibrinolysis and consumptive coagulopathy can cause early fatal intracranial or pulmonary bleeding. Large vascular abnormalities such as aortic aneurysm and vascular tumours can cause chronic compensated consumption. Severe transfusion reactions, snake envenomation and selected immune or transplant complications enter the differential depending on context, although venom-induced consumption coagulopathy is mechanistically distinct and should not automatically be called DIC.
Risk of clinical bleeding rises with falling platelets and fibrinogen, invasive procedures, uncontrolled source haemorrhage, obstetric injury, anticoagulant exposure, renal or hepatic dysfunction and delayed access to compatible components. Microvascular thrombosis and organ failure may dominate even without visible bleeding. A person may progress rapidly after an initially reassuring panel, so trend and clinical trajectory are risk variables. Pre-existing liver disease, thrombocytopenia or anticoagulant use complicates interpretation rather than proving DIC. In India, delayed transfer, unregulated pre-referral fluids, unavailable fibrinogen testing, incomplete drug history and fragmented blood-bank communication can increase harm. Risk assessment must identify the trigger, bleeding and thrombosis phenotype, planned procedures, baseline results and rate of change.
Diagnosis
History
Establish the precipitating illness and tempo: fever, shock, source symptoms, major trauma, burns, malignancy, recent chemotherapy, pregnancy or postpartum event, fetal loss, placental abruption, haemorrhage, transfusion, envenomation and surgery. Ask about oozing from lines, mucosal bleeding, haematuria, melaena, postpartum bleeding, bruising, dyspnoea, confusion, oliguria, acral pain and skin change. Record anticoagulants, antiplatelets, liver disease, prior platelet count and all fluids or components already given. In suspected APL, fatigue, infection and bleeding with cytopenias or abnormal promyelocytes require an emergency pathway.
Examination
Prioritise airway, breathing, circulation, mental state, temperature, perfusion and urine output. Look for diffuse venepuncture-site oozing, petechiae, ecchymoses, mucosal or wound bleeding, uterine atony and concealed abdominal, thoracic or retroperitoneal haemorrhage. Assess livedo, purpura fulminans, acral ischaemia and evidence of venous or arterial thrombosis. Seek trigger-specific findings, including infection source, placental abruption, retained products, trauma burden or malignancy. Visible bleeding may be absent while kidney, lung, liver, brain or skin microcirculation fails.
Investigations
Send full blood count with serial platelets, expert film, PT/INR, aPTT, fibrinogen and a fibrin-related marker such as D-dimer, plus renal, liver, lactate, blood gas and trigger-specific tests. Check group and screen or cross-match early. Apply an institutional score correctly: the classic ISTH overt score uses platelet count, fibrin marker increase, PT prolongation and fibrinogen in a compatible disorder. Repeat testing because DIC evolves. Schistocytes may occur but are neither required nor specific. Fibrinogen can remain normal or high early in sepsis; a falling trend is informative. The 2025 ISTH communication proposes updated early- and late-phase concepts, but laboratories and clinical systems need local implementation. Exclude sample clotting, heparin or direct-anticoagulant interference. Blood cultures and source imaging should not delay resuscitation or indicated antimicrobials. In possible APL, urgent morphology, coagulation studies and molecular confirmation must proceed with haemato-oncology involvement.
Differential Diagnosis
Severe liver disease produces prolonged PT and aPTT, thrombocytopenia and low fibrinogen, often with elevated D-dimer. Unlike a simplistic bleeding-only model, cirrhosis has rebalanced and fragile haemostasis with thrombotic as well as bleeding risk. Baseline history, factor patterns, liver findings and serial change help, but DIC may occur on top of liver disease. Vitamin K deficiency prolongs PT before aPTT and does not itself cause major D-dimer elevation or platelet consumption. Dilutional coagulopathy after massive crystalloid or red-cell resuscitation reflects loss and dilution of platelets and fibrinogen and can coexist with DIC.
Thrombotic thrombocytopenic purpura and other thrombotic microangiopathies cause thrombocytopenia, microangiopathic haemolysis and organ injury, but routine coagulation tests are often near normal because systemic consumption of coagulation factors is not central. Suspected TTP requires urgent ADAMTS13 sampling and treatment without waiting for the result. Haemolysis, elevated liver enzymes and low platelets in pregnancy may represent HELLP syndrome; obstetric DIC can coexist, particularly with abruption or major haemorrhage. Immune thrombocytopenia causes isolated thrombocytopenia rather than a consumptive coagulation profile.
Primary hyperfibrinolysis, massive pulmonary embolism, extracorporeal-circuit consumption, antiphospholipid syndrome and anticoagulant overdose can mimic parts of DIC. Heparin-induced thrombocytopenia is prothrombotic, has a characteristic exposure timeline and usually does not cause the full consumptive pattern unless complicated. Venom-induced consumption coagulopathy after snakebite can produce incoagulable blood but differs in pathophysiology and treatment, including antivenom. Postpartum haemorrhage can cause acute traumatic and dilutional coagulopathy without systemic DIC. A prolonged aPTT from lupus anticoagulant or heparin contamination is not DIC. Use the entire clinical context, baseline results, serial trend and a validated score; never diagnose DIC from D-dimer alone because infection, cancer, pregnancy, trauma and thrombosis independently elevate it.
Management
Treat the cause immediately. In sepsis, obtain appropriate cultures without delaying antimicrobials, give source-appropriate therapy, resuscitate perfusion and secure source control. In obstetric DIC, activate the obstetric massive-haemorrhage pathway and achieve delivery, uterine, placental or surgical control as indicated. In trauma, control haemorrhage, prevent hypothermia, correct hypocalcaemia and use protocolised balanced resuscitation. Suspected APL requires immediate haemato-oncology action because disease-specific therapy and aggressive coagulation support are time critical. DIC will not resolve through plasma alone while the trigger persists.
Use blood components for active clinically significant bleeding or a procedure with substantial bleeding risk, guided by examination, serial laboratory results and the local transfusion protocol. Platelets may be considered when bleeding or procedural risk coexists with severe thrombocytopenia; fresh frozen plasma can replace multiple depleted factors when bleeding and prolonged tests coexist. Cryoprecipitate or fibrinogen concentrate may be needed for clinically important hypofibrinogenaemia, subject to product availability and protocol. Transfusion is not indicated solely to make an abnormal test normal in a stable non-bleeding person. Monitor temperature, calcium, acid-base state and transfusion reactions.
Venous-thromboembolism prophylaxis remains important when bleeding risk permits. Therapeutic heparin may be considered when thrombosis predominates, such as purpura fulminans, acral ischaemia or selected chronic DIC, but requires specialist judgment. Evidence and product practice differ across DIC phenotypes: Japanese 2024 sepsis guidance on antithrombin or recombinant thrombomodulin is not automatically transferable to India, other causes or other regulators. Routine tranexamic acid is hazardous when fibrin deposition and impaired clearance are present; rare hyperfibrinolytic phenotypes such as selected APL cases need haemato-oncology direction. Reassess clinically and repeat platelets, PT, fibrinogen and fibrin markers at a frequency matched to instability. Escalate organ support early rather than waiting for an overt-score threshold.
Prescribing Information
DIC prescribing begins with the precipitating condition, not a universal anticoagulant. Antimicrobials for sepsis should follow suspected source, previous exposure, organ function, local antibiogram and current sepsis guidance, then narrow with microbiology. Vasopressors, fluids and corticosteroids follow shock physiology and a critical-care protocol. In APL, all-trans retinoic acid is disease-specific emergency therapy under haemato-oncology supervision; this page does not provide a dose or authorise use before an expert pathway. Obstetric uterotonics, tranexamic acid for postpartum haemorrhage and surgical therapies follow the obstetric haemorrhage protocol, which is distinct from giving antifibrinolysis simply because DIC has been named.
A blood component is a prescribed biological therapy. State indication, patient identifiers, component, amount or target, urgency, compatibility requirements and monitoring. Platelet thresholds are contextual: active major bleeding, central nervous system bleeding and procedures differ from stable non-bleeding thrombocytopenia. Plasma dosing must be sufficient to alter factor levels if clinically indicated, while volume overload is a real risk. Fibrinogen replacement should use a measured level or strong clinical indication and serial response. Red cells restore oxygen-carrying capacity but do not correct consumptive coagulopathy. Give calcium and warming according to massive-transfusion protocols, not reflexively outside them.
Therapeutic unfractionated heparin may be chosen when thrombosis predominates because it is titratable, yet baseline aPTT abnormalities complicate monitoring and anti-Xa assays can also be affected by critical illness. Low-molecular-weight heparin depends on renal function and reversibility needs. Avoid routine antifibrinolytics in unselected DIC; blocked fibrinolysis can worsen microvascular thrombosis. Antithrombin concentrate, recombinant thrombomodulin and other targeted agents have jurisdiction-specific approvals and evidence. Indian clinicians must confirm CDSCO status, institutional formulary and indication rather than import a Japanese recommendation. Every medicine and component decision needs contemporaneous reassessment because the syndrome can move from thrombotic to bleeding dominance within hours.
When to Refer
DIC is usually a hospital emergency, not an outpatient condition. Refer or escalate immediately when a compatible trigger is accompanied by falling platelets, prolonged PT, rising fibrin markers, falling fibrinogen, diffuse oozing, organ dysfunction, shock, purpura or suspected thrombosis. A district facility should contact the receiving critical-care, obstetric, trauma or haemato-oncology team early while beginning cause-specific resuscitation. Do not wait for every component of a score if sepsis, abruption, APL or major trauma requires time-critical treatment.
Specialty routing follows the trigger and dominant threat. Obstetric haemorrhage needs senior obstetrics, anaesthesia, blood bank, interventional radiology or surgery as locally available. Suspected APL requires immediate haemato-oncology and transfusion support. Trauma demands a major-haemorrhage team and definitive bleeding control. Sepsis with shock or organ dysfunction requires critical care and source-control expertise. Purpura fulminans, acral ischaemia or macrovascular thrombosis benefits from haematology and relevant vascular or surgical input. TTP in the differential requires urgent plasma-exchange-capable haematology referral.
Before transfer, communicate the trigger, vital trends, urine output, neurological state, bleeding sites, pregnancy status, all laboratory values with times, score used, cultures, imaging, fluids, medicines and components. Send samples before transfusion when this will not delay care. Confirm that the receiving unit has blood-component availability and the required procedural capability; transferring an unstable patient without haemorrhage control or resuscitation can be fatal. Where transport is prolonged, obtain senior advice on components and monitoring en route. After recovery, refer for evaluation of an unexplained trigger, malignancy, vascular lesion or recurrent consumption. Survivors of severe sepsis or obstetric catastrophe also need organ, psychological and functional follow-up; normalised coagulation tests do not erase the consequences of the critical illness.
Red Flags
Shock, altered mental status, oliguria, hypoxaemia, rising lactate or rapidly worsening acidosis indicates failing organ perfusion and demands immediate resuscitation and cause control. Diffuse puncture-site oozing, haematemesis, melaena, haematuria, postpartum haemorrhage, haemoptysis, expanding wounds or suspected intracranial bleeding are haemorrhagic emergencies. A rapidly falling platelet count or fibrinogen can be more informative than an isolated value. Normal fibrinogen does not reassure when sepsis is inflamed and the level is dropping.
Purpura fulminans, retiform purpura, cold painful digits, cyanosis, limb ischaemia or new venous or arterial thrombosis signals severe thrombin generation. DIC can therefore worsen when clinicians respond to every abnormal test with pro-haemostatic therapy without considering thrombosis. New renal, hepatic, respiratory or neurological dysfunction may reflect microvascular injury even with little external bleeding. In a pregnant or postpartum patient, abdominal pain, uterine tenderness, fetal compromise, concealed blood loss or abrupt cardiovascular collapse requires simultaneous obstetric and DIC action.
Abnormal promyelocytes, pancytopenia or leucocytosis with bruising, mucosal bleeding, headache or low fibrinogen raises acute promyelocytic leukaemia; do not delay the emergency pathway for complete molecular classification. Fever and hypotension after transfusion may be sepsis, an acute haemolytic reaction or progression of the original illness; stop the component, check identity and activate transfusion investigation while resuscitating. Sudden thrombocytopenia after heparin exposure raises HIT, which requires a different anticoagulant strategy. Schistocytes with neurological or renal injury and relatively normal coagulation tests raises TTP, for which delay in plasma exchange is dangerous. These red flags illustrate why the label DIC must trigger repeated diagnostic review rather than diagnostic closure.
Indian Clinical Context
Indian DIC care spans tertiary intensive-care and haemato-oncology units, obstetric referral centres, trauma services, district hospitals and facilities with limited coagulation or blood-bank capability. A minimum pathway should secure serial platelet count, PT/INR and fibrinogen where possible, early group and screen, bedside detection of bleeding and organ dysfunction, cause-directed treatment and a pre-agreed transfer threshold. D-dimer availability and reporting range vary; a qualitative positive result cannot be inserted into a quantitative scoring category without laboratory validation. Point-of-care viscoelastic testing can support selected major-haemorrhage services but neither access nor interpretation is universal.
Component supply is constrained by donation, testing, storage and transport. Plasma cannot substitute for fibrinogen-rich therapy when fibrinogen is critically low, and red cells cannot replace platelets or clotting factors. Each institution should map 24-hour availability of platelets, plasma, cryoprecipitate and fibrinogen concentrate and specify activation contacts. Uncrossmatched emergency red-cell use, group-specific transition and massive-transfusion ratios belong in the local protocol. Unnecessary prophylactic transfusion consumes scarce components and exposes patients to overload and reactions.
International guidance needs jurisdictional translation. The BSH document remains useful for core diagnostic and component principles but dates from 2009 with a 2012 review. The 2024 Japanese DIC recommendations reflect Japanese diagnostic systems, products and evidence assessment. The 2025 ISTH communication advances definition and scoring, but local laboratories must validate implementation. Surviving Sepsis guidance is international and does not encode each Indian antibiogram, staffing pattern or access constraint. Indian epidemiological and comparative-treatment data remain incomplete. Hospitals should audit maternal, sepsis, trauma and APL pathways separately; publish score choice, sampling intervals and component triggers; and record delay and outcome. This draft makes no claim that all listed assays, medicines or blood products are uniformly available or licensed throughout India.
NMC Competency Mapping
NMC CBME Curriculum 2024 Pathology competency PA20.2 explicitly requires the student to define and describe disseminated intravascular coagulation, its laboratory findings and its diagnosis, alongside diagnosis of vitamin K deficiency. PA20.1 supplies the normal-haemostasis, vascular, platelet and haemophilia foundation. Blood-bank competencies PA21.1 to PA21.6 cover blood groups, components and their clinical uses, transfusion-transmitted infection, transfusion reactions, autologous transfusion, grouping and cross-matching. These outcomes directly support safe reasoning about consumptive coagulopathy and components.
An undergraduate should explain how systemic thrombin generation produces both microvascular fibrin and consumption, identify major triggers, recognise bleeding and organ-failure phenotypes, and interpret platelet count, PT, aPTT, fibrinogen and D-dimer as a serial pattern. They should distinguish DIC from isolated vitamin K deficiency, liver disease, TTP, dilutional coagulopathy and anticoagulant effect. They should know that treating the underlying cause is central, that a score complements rather than replaces clinical assessment, and that plasma or platelets are not prescribed solely for abnormal numbers in a stable non-bleeding patient.
Integrated teaching should involve pathology, medicine, paediatrics, obstetrics, surgery, emergency medicine, anaesthesia, pharmacology, microbiology and transfusion medicine. Useful cases include septic shock with falling platelets, abruption with haemorrhage, APL with low fibrinogen and purpura fulminans. Learners can calculate the established ISTH overt score when complete values are supplied, but should state its limits in early disease and name the scoring version. Curriculum achievement does not credential independent massive-transfusion activation, blood-component dosing, anticoagulation in DIC, APL therapy, obstetric source control or ICU management; these are supervised, protocol-bound actions.
Key Exam Pearls for NEET PG
DIC is acquired systemic activation of coagulation with fibrin formation, consumption of platelets and factors, secondary fibrinolysis, bleeding and microvascular thrombosis. Classic triggers are sepsis, obstetric catastrophe, major trauma and malignancy, especially acute promyelocytic leukaemia. Laboratory findings commonly include thrombocytopenia, prolonged PT, elevated D-dimer or fibrin-degradation markers and reduced fibrinogen. aPTT may prolong but can be normal. Fibrinogen can be normal or elevated early in sepsis because it is an acute-phase reactant; a falling trend matters.
The established ISTH overt score combines platelet count, fibrin-related marker increase, PT prolongation and fibrinogen in a patient with a compatible disorder. A positive score supports overt DIC and serial reassessment is required. The 2025 ISTH communication updates the definition and proposes earlier, cause-aware phases, so an exam question should specify which criteria it expects. Schistocytes may appear but are not required. D-dimer is sensitive to fibrin turnover but not specific for DIC.
TTP produces thrombocytopenia and microangiopathic haemolysis with usually near-normal PT and aPTT; vitamin K deficiency prolongs PT without platelet consumption or marked fibrin generation; severe liver disease can closely mimic DIC. Treat the underlying cause first. Give platelets or plasma for significant bleeding or a high-risk procedure rather than numbers alone. Heparin is not routine for bleeding-predominant acute DIC but may be considered when thrombosis dominates. Antifibrinolytics are generally avoided in unselected DIC. APL-associated coagulopathy demands immediate specialist disease-specific therapy and intensive transfusion support. For NMC, PA20.2 is the direct anchor, with PA21 covering component use and transfusion reactions.
Frequently Asked Questions
Can a high D-dimer by itself diagnose disseminated intravascular coagulation?
No. D-dimer rises in infection, pregnancy, cancer, trauma, venous thromboembolism and after surgery. DIC requires a compatible underlying disorder plus a clinical and serial laboratory pattern. Platelets, PT, fibrinogen and fibrin markers should be interpreted through a named validated score while the team repeatedly reassesses bleeding, thrombosis and organ function.
Does a normal fibrinogen concentration exclude early sepsis-associated DIC?
No. Fibrinogen is an acute-phase reactant and may remain normal or high despite consumption, especially early in sepsis. A falling value, together with platelet decline, PT change, rising fibrin markers and organ dysfunction, can be more informative. Clinical deterioration should not wait for fibrinogen to fall below a reference interval.
Should plasma or platelets be given to every patient with abnormal DIC tests?
No. Component therapy is generally reserved for clinically significant bleeding, a high-risk procedure or a protocol-defined major haemorrhage, with thresholds adapted to the site and patient. Treating numbers alone can cause volume overload, reactions and scarce-resource loss. Serial response and control of the underlying cause are essential.
Can the Japanese 2024 DIC drug recommendations be copied directly into Indian practice?
No. Those recommendations use Japanese diagnostic systems, products, regulatory context and evidence interpretation. Antithrombin, recombinant thrombomodulin, heparin and antifibrinolytics cannot be generalised across all DIC causes. Indian licensing, formulary access, local protocols, bleeding phenotype and specialist assessment must govern treatment, and limitations should be documented explicitly.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic